An analysis of neuroblastoma at a single institution.
Between 1949 and 1978, 119 children with the diagnosis of neuroblastoma or ganglioneuroblastoma were treated at the Washington University Medical Center. Of these, 50 (41%) were alive and disease-free 3 or more years after diagnosis. Important prognostic variables included stage of tumor (Evans staging), histology, age at diagnosis, and site of primary tumor. A stepwise logistic regression analysis of these data has shown that, in order of significance, stage, histology and age at diagnosis are independent prognostic variables. Sex of the patient and nodal status at diagnosis (where known) were not significant prognostic variables. No effects of individual treatment modalities could be detected. This study confirms the overwhelming influence of factors unrelated to treatment in determining the prognosis of neuroblastoma.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005728:Ganglia, Sympathetic; D005729:Ganglioneuroma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008207:Lymphatic Metastasis; D008297:Male; D009423:Nervous System Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009447:Neuroblastoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D014805:Vitamin B 12 / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014805:Vitamin B 12